Novo Nordisk/Aradigm Inhaled Insulin Study For Type 1 Diabetes Raises Efficacy Concern
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical focus could shift solely to type 2 diabetes. Interim analysis shows unexpected delay in post-meal glucose suppression, but Novo and Aradigm say positive safety results make data “very usable in our regulatory filing.”
You may also be interested in...
Novo Nordisk Inhaled Insulin To Resume Phase III Studies
Trials for the AERx inhaled insulin system will involve both type 1 and type 2 diabetes, despite a previous safety signal in type 1 patients.
Novo Nordisk Inhaled Insulin To Resume Phase III Studies
Trials for the AERx inhaled insulin system will involve both type 1 and type 2 diabetes, despite a previous safety signal in type 1 patients.
Kos Inhaled Insulin Comparable To Lantus In Phase IIa Trial, Firm Says
Kos' inhaled insulin formulation demonstrated equivalent efficacy and safety compared to Aventis' injectable basal insulin analog Lantus in a Phase IIa study, the firm reported Aug. 26